Progenity PROG 深 沪
已收盘 05-06 16:00:00 美东时间
0.8845
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.8845
- 总市值 1.63亿
- 52周最高 1550.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 164.25
- 委 比 0.00%
- 总股本 1.84亿
- 历史最高 3980.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 164.25
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BTIG Maintains Sell on PROG Holdings, Raises Price Target to $31
BTIG analyst Vincent Caintic maintains PROG Holdings (NYSE:PRG) with a Sell and raises the price target from $27 to $31.
10-23 18:06
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
10-23 00:07
PROG Holdings Raises FY2025 Adj EPS Guidance from $3.20-$3.35 to $3.35-$3.45 vs $3.33 Est; Lowers FY2025 Sales Guidance from $2.450B-$2.500B to $2.410B-$2.435B vs $2.474B Est
PROG Holdings (NYSE:PRG) raises FY2025 Adj EPS guidance from $3.20-$3.35 to $3.35-$3.45 vs $3.33 analyst estimate. Lowers FY2025 sales outlook from $2.450 billion-$2.500 billion to $2.410 billion-$2.435 billion vs $2.474
10-22 19:37
PROG Holdings Q3 Adj. EPS $0.90 Beats $0.74 Estimate, Sales $595.100M Beat $586.113M Estimate
PROG Holdings (NYSE:PRG) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.74 by 21.62 percent. This is a 16.88 percent increase over earnings of $0.77 per share from the same
10-22 19:32
Earnings Scheduled For October 22, 2025
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is estimated to repor...
10-22 16:32
Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause
Progyny, a global leader in women's health, launched new programs for global employers addressing pregnancy, postpartum, and menopause, available from January 1, 2026. These offerings integrate with their existing fertility solutions, providing a continuum of care supported by localized expertise. Employees gain access to personalized consultations, a knowledge center, country-specific navigator support, and a GDPR-compliant platform. The program...
10-22 13:28
Alector Discontinues Open-Label Extension For Latozinemab; Co To Reduce Workforce By About 49%
Alector Pipeline OutlookAlector remains focused on advancing a pipeline of programs designed to treat neurodegenerative diseases through mechanisms that remove toxic proteins, replace deficient proteins, and restore
10-22 04:35
PROG Holdings Earnings Preview
PROG Holdings (NYSE:PRG) is preparing to release its quarterly earnings on Wedn...
10-22 04:02
Lexicon Pharma Presents Additional Clinical Data And Program Updates From Phase 2 Pilavapadin Program At 19th Annual Pain Therapeutics Summit
– Results support advancement of 10 mg dose into Phase 3 development –– End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing –THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) --
10-14 20:02
Edwards Lifesciences upgraded at Evercore on upcoming 'topline inflection'
Evercore ISI upgraded Edwards Lifesciences (NYSE:EW) to outperform from equal weight as it sees "a topline inflection around the corner." The firm set a price target of $88 (~15% upside based on Oct. ...
10-08 01:16
